Member Info for Formul1187

Buy on the phone

N4 Pharma Make considerable progress on Nuvec, well positioned for collaborations (Interview) February 25, 2021

Moved forward as pace since last November Theobald is not to be underestimated

Top up not nt

TOP AIM STOCKS
@************
·
6m
Every company will need us patented in OZ/USA this is a multi-bagger in waiting listen 2 the interview #N4P #Nuvec #viralvaccines #cancertreatments
@n4pharma

https://mobile.twitter.com/hashtag/n4p?f=live

Pivotal time great interview

Very Strong position in market

Yea just tried again

https://www.***************************/n4-pharma-make-considerable-progress-on-nuvec,-well-positioned-for-collaborations-interview/412963831

Just a little swing trending seriously north

TOP AIM STOCKS
@************
·
51m
FFS GUYS THIS IS IT https://dailymail.co.uk/news/article-9295163/Brits-Covid-vaccine-PILL-future-Oxford-University-says.html…

Get ready for the RocketRocketRocketRocketRocketRocketRocketRocketRocketRocket #N4P
@n4pharma

Dodge coin day today arb looking good at this price

Already baggged more bags coming

Upwards trend not broken yet

TOP AIM STOCKS
@************
·
1h
Replying to
@cas1878
I am a big buyer of #N4P and have been for months and will keep buying

: N4 Pharma is well-positioned to offer developers an alternate delivery approach
for their DNA/RNA-based vaccine candidates. Supported by cash from a placing in May, N4P
is nearing completion of its COVID-19 programme. Positive results from this project would
be a significant milestone for the Group. Through the optimisation programme N4 Pharma
looks to progress Nuvec® to a stage where it can seek licencing agreements. We expect
interest from potential partners seeking to use Nuvec® as part of their development
programme for nucleic acid-based products.

Manufacturing scale up of Nuvec®
Currently N4 Pharma and its collaborators can manufacture Nuvec® in the small
amounts required for lab-based testing. The Group is now looking to scale-up
manufacturing capabilities for Nuvec®. This would provide sufficient resources for laterstage preclinical work and demonstrate to potential partners that Nuvec® can be
manufactured at adequate quantities for clinical trials. This work is supported by the
proceeds from the May 2020 fundraise. In September, N4 Pharma appointed Ardena, a
Dutch-based contract development and manufacturing organisation (CDMO), as its
partner for the technology transfer and upscaling manufacture of Nuvec®.

sng money still loading up here rns still due

250k buyer very active follow the money strong up wards trend still in motion from 4p